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What is Lynch Syndrome?
Statement of Problem
 No standardized  approach to screening patients for LS to determine if 
germline testing is appropriate. 
 Germline testing is required to identify mutation carriers.
 Universal testing of all colorectal cancer is no longer done due to cost 
and low occurrence.
 When ever possible the ‘proband’ should be tested, and the tumor  
when available.  
Research Question
Literature Review
Applicability to Clinical 
Practice 
Discussion
• Also known as hereditary nonpolyposis colorectal cancer (HNPCC)
• Malignant tumors associated with Lynch Syndrome progress more rapidly 
through stages and are commonly diagnosed at an earlier age.
• Cancer most commonly associated with LS is colorectal and endometrial.   
• Affected individuals are also at an increased risk of developing other 
cancers: stomach, ovarian, biliary, and renal cancers.  
• LS carcinomas are characterized by a progressive accumulation of genetic 
damage resulting in injury. 
• Injury is detected through evidence of short tandem repeats of DNA, 
normally these should be of equal length, and referred to as microsatellites 
• Microsatellite instability (MSI) refers to changes in 2 or more of the 5 
microsatellite markers. MSI alone lacks specificity (limited screening tool)  
• Immunohistochemistry (IHC), screens for mismatch repair proteins, 
identifying, MLH1, MSH2, MSH6 and PMS2. 
• An abnormal IHC implies at least one of the proteins is not expressed. 
• IHC is an alternative screening tool, can be used in combination with MSI.  
“Red Flags” for patients who do not have cancer
 An individual or family history of the following:
2 or more relatives with a Lynch syndrome (LS) cancer, one before 
the age of 50
3 or more relatives with a LS cancer at any age.
A previously identified LS mutation in the family. 
 Prediction models are indicated when the:
 individual does not have colorectal cancer (CRC) 
 individual is without a family member with CRC or the family is 
unwilling to have tumor tested.  
 Patients with a strong history suggestive of LS can be screened in 
office with use of the PREMM model.
 PREMM model prediction score can aid providers in guiding patients 
care. 
 PREMM model can be utilized at http://dana-farber.org/premm
A negative result on a prediction model could eliminate the need to 
refer for genetic counseling for germline sequencing. 
 If the PREMM score is >5% the patient should be referred to genetic 
counseling. 
Patients identified with Lynch Syndrome mutation
Colonoscopy at age 20-25 years or 2-5 years earliest colon cancer 
if diagnosed <25 years of age.
Repeat colonoscopy every 1-2 years
Prophylactic hysterectomy and bilateral salpingo-oophorectomy 
for women who have completed childbearing.
Any dysfunctional uterine bleeding warrants work-up
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In clinical practice, a thorough personal and family history will remain 
clinician’s best approach to screening for a hereditary cancer family risk.
(Katrinos, Balmana & Synga 2013)
Abstract
Lynch syndrome is an autosomal dominant syndrome caused by 
an inherited germline mutation of the MMR proteins. A mutation of any 
of the MMR proteins, MLH1, MSH2, MSH6, PMS2 and EPCAM 
increases the risk of developing cancer, specifically colorectal and 
endometrial cancer. Approximately 3% of colorectal cancers are 
associated with Lynch Syndrome (LS). Early identification of a patient’s 
hereditary cancer risk offers the best outcome. To aid clinicians in the 
identification of a carrier of LS clinical guidelines and risk prediction 
models are used. In this analysis the Amsterdam II criteria and Revised 
Bethesda guidelines are compared to the more recent prediction models, 
PREMM, MMRpro and MMRpredict to identify if further tumor testing 
or germline sequences should be considered. A meta-analysis comparing 
clinical criteria to the predication models produced results identifying 
the prediction models with both a specificity and sensitivity of >90% of 
predicting MMR protein mutations (Win , 2013). The performance of 
each model compared to Amsterdam or Bethesda guidelines was found 
to exceed the clinical criteria’s ability to discriminate LS carriers from 
noncarriers (Katrinos, Balmana,& Syngal, 2013). 
o Clinical suspicion of LS was originally based on Amsterdam criteria, 
but was too stringent and only identifying 60% of patients. They were 
revised in 1998, increasing sensitivity to 80%.
o Bethesda guidelines were developed by the National Cancer Institute 
in the advent of molecular testing, revised in 2004. 
o Revised Bethesda guidelines added indicators improving sensitivity, 
CI 86-92%, but specificity 49-58%.   
o Prediction models were found to be sensitive and specific at >90% of 
predicting MMR gene mutation carriers.
o Kidambi et al. conducted a 6 year retrospective study that screened 
patients ‘selectively’. CRC less than 60 years old, suggestive MSI 
histology or previous LS cancer. Selective screening was similar to 
the Revised Bethesda guidelines. These results were compared to that 
of ‘universally’ screening all colorectal cancers (2014).
o Amsterdam criteria and components of the Revised Bethesda 
guidelines are quite complex and are not designed to determine the 
likelihood of an individual carrying a genetic mutation (Katrinos, 
Balmana, & Syngal, 2013)
o Win et al., conducted a meta-analysis reviewing 12 criteria/guidelines, 
including the Amsterdam and Bethesda guidelines, and prediction 
models (2013)
o The values from the analysis for MMRpro was 0.80 with a 95% CI, 
MMRpredict was 0.81 with a 95% CI, and PREMM was 0.84 with a 
95% CI (Win, 2013).
o Katrinos, et al. (2013) conducted a study comparing the PREMM 
model with MSI and IHC tumor testing. 1,868 unrelated patients with 
colorectal cancer were recruited through the Colon Cancer Family 
Registry. A univariate analysis was then conducted. 
o Journal National Cancer Institute reported a study that was conducted 
to compare cost effectiveness of the two screening strategies, clinical 
criteria compared to that of prediction models, and all were followed 
by either IHC then germline testing or direct germline testing (Barzi, 
2015).
o Predictive models in initial screening has comparable sensitivity to 
that of universal screening of all CRC with IHC, further stating that 
prediction models are effective in evaluating hereditary risk of Lynch 
syndrome and should be considered as a quality-of-care measure 
(Barzi, 2015).
 Kastrinos, et al.(2013), indicated that PREMM, had better results of 
distinguishing mutation carriers from non-carriers in the entire cohort. 
Similarily, according to Katrinos, Balmana & Syngal (2013), the 
PREMM model selected 20% more individuals than the Revised 
Bethesda guidelines. With high-quality information a negative 
screening could eliminate the need to refer for molecular or genetic 
testing for Lynch Syndrome (Barzi, 2015).
There is ample evidence that each of the models have superior 
performance characteristics in terms of sensitivity, specificity, positive 
and negative predictive values to support the use of models over the 
existing clinical guidelines for the diagnosis and evaluation for Lynch 
syndrome. (Katrinos, Balmana, & Syngal, 2013, p. 7-8)
